Paper Review Records
All Paper Review Records
12 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Re: Develtere D, Devos G. Metformin in prostate cancer: A negative repurposing story across the disease continuum. Urol Oncol 2026. https://doi.org/10.1016/j.euo.2026.04.014
Cameron E. Alexander; Ashwin Sachdeva; Noel W. ClarkeShow moreShow less
Department of Surgery, The Christie NHS Foundation Trust, Manchester, UK; Genitourinary Cancer Research Group, Division of Cancer Sciences, University of Manchester, UK; Department of Urology, Salford Royal Hospital, Manchester, UKShow moreShow less
Predicting the Development of BCG-unresponsive Disease Among Patients with High-grade Non-muscle-invasive Bladder Cancer: An International Multicenter Analysis
Aleksander Ślusarczyk; Marco Moschini; Wojciech Krajewski; Pietro Scilipoti; Roberto Contieri; Francesco Claps; José Daniel Subiela; Laura S. Mertens; Keiichiro Mori; Jorge Caño Velasco; Francesco Soria; Elisabeth Grobet-Jeandin; Karl Tully; Karolina Garbas; Pedro Del Olmo Durán; Renee A.G. Lijnen; Giorgia Fertitta; Maxence Reynard; Olga Katzendorn; Alfonso Lafuente Puentedura; Mattia Longoni; David D’Andrea; Francesco Del Giudice; Andrea Gallioli; Ekaterina Laukhtina; Gautier Marcq; Andrea Mari; Luca Afferi; Simone Albisinni; Antonio Amodeo; Stephen A. Boorjian; Alberto Briganti; Francesco Montorsi; Shahrokh F. Shariat; Paolo Gontero; Piotr Radziszewski; Benjamin PradereShow moreShow less
Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland; Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy; Department of Urology and Oncologic Urology, Wrocław Medical University, Wroclaw, Poland; Department of Urology, National Cancer Institute, IRCCS Fondazione G. Pascale, Naples, Italy; Oncological Urology, Veneto Institute of Oncology, Padua, Italy; Department of Urology, Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Madrid, Spain; Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan; Department of Urology, Clínica Universidad de Navarra, Cancer Center, Pamplona, Spain; Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy; Division of Urology, Geneva University Hospitals, Geneva, Switzerland; Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany; Department of Urology, UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France; Department of Urology, Gregorio Marañón University Hospital, Madrid, Spain; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Maternal, Infant, and Urologic Sciences, “Sapienza” University of Rome, Policlinico Umberto I Hospital, Rome, Italy; Department of Urology, Fundació Puigvert, Autonomous University of Barcelona, Barcelona, Spain; Department of Urology, Claude Huriez Hospital, Centre Hospitalier Universitaire (CHU) Lille, Lille, France; Department of Urology, University of Florence, Careggi Hospital, Florence, Italy; Department of Urology, Aarau Kantonsspital, Aarau, Switzerland; Urology Unit, Department of Surgical Sciences, Policlinico Tor Vergata, Tor Vergata University, Roma, Italy; Department of Urology, Mayo Clinic, Rochester, MN, USA; Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Department of Urology, Semmelweis University, Budapest, HungaryShow moreShow less
Study Protocol of OLIGOPELVIS 2-GETUG P12: A Randomized Phase 3 Study Comparing Intermittent Androgen-deprivation Therapy with or Without Salvage High-dose Intensity-modulated Radiotherapy to Oligorecurrent Pelvic and Para-aortic Lymph Nodes in Patients with Biochemically Relapsing Prostate Cancer
Quentin Josset; Audrey Blanc-Lapierre; Grégoire Pigne; Lysian Cartier; David Pasquier; Philippe Ronchin; Guillaume Bera; Ali Hasbini; Benjamin Schipman; Jonathan Khalifa; Paul Sargos; Magali Quivrin; Ulrike Schick; Frédéric Mallet; Cecile Laude; Clotilde Morand; Geneviève Loos; Loig Vaugier; Ke Zhou; Nathalie Mesgouez-Nebout; Stéphane SupiotShow moreShow less
Department of Radiation Oncology, Institut de Cancérologie de l’Ouest, Nantes, Angers, France; Department of Biostatistics, Institut de Cancérologie de l’Ouest, Boulevard J. Monod, Nantes, St-Herblain, France; Department of Radiation Oncology, Institut de Cancérologie de la Loire, St-Priest-en-Jarez, France; Department of Radiation Oncology, Institut Sainte Catherine, Avignon, France; Academic Radiation Oncology Department, Centre Oscar Lambret, Lille, France; Department of Radiation Oncology, Centre Azuréen de Cancérologie, Mougins, France; Department of Radiation Oncology, Centre Hospitalier (CH) Bretagne Sud, Lorient, France; Department of Radiation Oncology, Clinique Pasteur, Brest, France; Department of Radiation Oncology, Institut de Cancérologie de Bourgogne, Dijon, France; Department of Radiation Oncology, Institut Claudius Regaud, Toulouse, France; Department of Radiation Oncology, Institut Bergonie, Bordeaux, France; Department of Radiation Oncology, Centre Georges François Leclerc, Dijon, France; Department of Radiation Oncology, Centre Hospitalier Régional Universitaire (CHRU) Morvan, Brest, France; Department of Radiation Oncology, Institut de Cancer Courlancy, Reims, France; Department of Radiation Oncology, Centre Léon Bérard, Lyon, France; Department of Radiation Oncology, Centre Hospitalier Départemental (CHD) Vendée, La Roche-sur-Yon, France; Department of Radiation Oncology, Centre Jean Perrin, Clermont-Ferrand, France; Centre National de la Recherche Scientifique (CNRS) Unité en Sciences Biologiques et Biotechnologiques (US2B), Nantes University, Nantes, FranceShow moreShow less
Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 Study
Philipp Cornelius Mandel; Mike Wenzel; María Natalia Gandur Quiroga; Maria T. Bourlon; Felix Chun; Zin W. Myint; Laura Bernal; Ray Manneh Kopp; Maria José Juan Fita; Thomas Büttner; Ondrej Fiala; Haoran Li; Martin Bögemann; Tomas Buchler; Diana Matthews; Alessandro Rizzo; Francesco Ciccimarra; Fernando Sabino Marques Monteiro; Andrey Soares; Francesco Massari; Thomas Steuber; Matteo SantoniShow moreShow less
Department of Urology, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany; Martini-Klinik Prostate Cancer Center & Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Instituto de Oncologia Ángel H. Roffo, Buenos Aires, Argentina; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; Division of Medical Oncology, Markey Cancer Center, University of Kentucky, Lexington, KY, USA; Clínica Universitaria Colombia Sanitas - Clínica Marly, Colombia; Clinical Oncology, Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia; Medical Oncology, Fundación Instituto Valenciano de Oncología, Valencia, Spain; Department of Urology, University Hospital Bonn (UKB), Bonn, Germany; Department of Oncology and Radiotherapeutics, Faculty of Medicine, University Hospital in Pilsen, Charles University, Pilsen, Czech Republic; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Cancer Center, Westwood, KS, USA; Department of Urology, University Hospital Münster, Münster, Germany; West German Cancer Center, Münster, Germany; Department of Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic; Velindre Cancer Centre, Velindre Road, Whitchurch, Cardiff CF14 2TL, Wales, UK; S.S.D. c.O.r.o. Bed Management Presa in Carico, TDM, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, Italy; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil; Hospital Sírio-Libanês, Brasília, DF, Brazil; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy; Medical Oncology Unit, Macerata Hospital, Macerata, ItalyShow moreShow less
AI-MIRACLE: Artificial Intelligence and MultIpaRAmetric MRI Predict CLinical OutcomEs to Neoadjuvant Immunotherapy in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy
Andrea Necchi; Giorgio Brembilla; Karissa Whiting; Yuki Arita; Oguz Akin; Aditya Apte; Muhammad Awais; Alfonso Lema-Dopico; Ramesh Paudyal; Michele Cosenza; Brigida Anna Maiorano; Valentina Tateo; Antonio Cigliola; Chiara Mercinelli; Francesco De Cobelli; Marinela Capanu; Amita Shukla-Dave; Lawrence H. SchwartzShow moreShow less
Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy; Department of Medical Oncology, Vita-Salute San Raffaele University, Milan, Italy; Department of Radiology, IRCCS San Raffaele Hospital, Milan, Italy; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, USAShow moreShow less
Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non-muscle-invasive Bladder Cancer: An Expert Consensus
Paolo Gontero; Richard Perry; Daisy Bridge; Diane Dalila Delattre; Sebastian Vosgerau; Robin Wyn; Medi Stone; Marek BabjukShow moreShow less
Department of Urology, University of Turin School of Medicine, Italy; Adelphi Values PROVE, Bollington, UK; Ferring Pharmaceuticals, Kastrup, Denmark; Department of Urology, 2nd Faculty of Medicine, Charles University, University Hospital Motol and Homolka, Prague, Czech RepublicShow moreShow less
FAQ
How long does European Urology Oncology take to review a manuscript?
As of 2026-11-19, CrushSCI has 12 complete review records for European Urology Oncology. The fastest paper went from submission to acceptance in 7 days (Re: Michael Baboudjian, Alessandro Uleri, Julien Anract, et al. Targeted, Perilesional, and Distant Biopsies in Prostate Cancer. Eur Urol Oncol. In press. http://dx.doi.org/10.1016/j.euo.2026.02.006, received 2026-03-10, accepted 2026-03-17); the slowest took 308 days. The average is 116.9 days and the median is 112 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
